Press Release – New York, NY – June 1, 2026 – Sichenzia Ross Ference Carmel LLP announced today that it represented BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, in the pricing of its $4.7 million best-efforts offering.
The SRFC team was led by partners Gregory Sichenzia and Avital Perlman, with associates Benasz Hansotia and Brady Berman.